A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)

NCT00251589 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
23
Enrollment
INDUSTRY
Sponsor class

Stopped This trial is being closed based on lack of substantive efficacy, slow accrual and overall tolerance in patients treated to date.

Conditions

Interventions

Sponsor

Merck Sharp & Dohme LLC